Oncos Therapeutics, a Helsinki, Finland-based biotech company developing new cancer therapeutics, completed a €4m (approximately $5.5m) investment from HealthCap, a specialized providers of venture capital within life sciences in Europe.
After treating over 200 late stage cancer patients since 2007 (through the Advanced Therapy Access Program, which is based on extensive scientific research at the University of Helsinki) with strong efficacy results, the company will use the funds to develop its lead clinical candidate, the oncolytic adenovirus CGTG-102, into cancer treatments.
Commenting on the possibilities of the company to develop, Dr Johan Christensen, partner at HealthCap, said: “Oncolytic viruses are maturing as a new treatment modality in cancer. Oncos, as one of the leading companies in the field, combines very promising results in humans with strong science”.
FinSMEs
29/04/2010